16 research outputs found
Radical Mediated C–H Functionalization of 3,6-Dichloropyridazine: Efficient Access to Novel Tetrahydropyridopyridazines
A radical
mediated C–H functionalization of 3,6-dichloropyridazine
using primary alcohols, <i>t</i>-BuOOH, and TiCl<sub>3</sub> to access alkoxy pyridazines is described. This transformation is
conducted open to air and on gram scale. A subsequent cyclization
step can then be employed to efficiently access diversely substituted
tetrahydropyridopyridazines with multiple functional handles
Radical Mediated C–H Functionalization of 3,6-Dichloropyridazine: Efficient Access to Novel Tetrahydropyridopyridazines
A radical
mediated C–H functionalization of 3,6-dichloropyridazine
using primary alcohols, <i>t</i>-BuOOH, and TiCl<sub>3</sub> to access alkoxy pyridazines is described. This transformation is
conducted open to air and on gram scale. A subsequent cyclization
step can then be employed to efficiently access diversely substituted
tetrahydropyridopyridazines with multiple functional handles
Structure-kinetic relationships--an overlooked parameter in hit-to-lead optimization: a case of cyclopentylamines as chemokine receptor 2 antagonists
Preclinical models of inflammatory diseases (e.g., neuropathic pain, rheumatoid arthritis, and multiple sclerosis) have pointed to a critical role of the chemokine receptor 2 (CCR2) and chemokine ligand 2 (CCL2). However, one of the biggest problems of high-affinity inhibitors of CCR2 is their lack of efficacy in clinical trials. We report a new approach for the design of high-affinity and long-residence-time CCR2 antagonists. We developed a new competition association assay for CCR2, which allows us to investigate the relation of the structure of the ligand and its receptor residence time [i.e., structure-kinetic relationship (SKR)] next to a traditional structure-affinity relationship (SAR). By applying combined knowledge of SAR and SKR, we were able to re-evaluate the hit-to-lead process of cyclopentylamines as CCR2 antagonists. Affinity-based optimization yielded compound 1 with good binding (Ki = 6.8 nM) but very short residence time (2.4 min). However, when the optimization was also based on residence time, the hit-to-lead process yielded compound 22a, a new high-affinity CCR2 antagonist (3.6 nM), with a residence time of 135 min
Recommended from our members
Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists.
CC chemokine receptor 2 (CCR2) is one of 19 members of the chemokine receptor subfamily of human class A G-protein-coupled receptors. CCR2 is expressed on monocytes, immature dendritic cells, and T-cell subpopulations, and mediates their migration towards endogenous CC chemokine ligands such as CCL2 (ref. 1). CCR2 and its ligands are implicated in numerous inflammatory and neurodegenerative diseases including atherosclerosis, multiple sclerosis, asthma, neuropathic pain, and diabetic nephropathy, as well as cancer. These disease associations have motivated numerous preclinical studies and clinical trials (see http://www.clinicaltrials.gov) in search of therapies that target the CCR2-chemokine axis. To aid drug discovery efforts, here we solve a structure of CCR2 in a ternary complex with an orthosteric (BMS-681 (ref. 6)) and allosteric (CCR2-RA-[R]) antagonist. BMS-681 inhibits chemokine binding by occupying the orthosteric pocket of the receptor in a previously unseen binding mode. CCR2-RA-[R] binds in a novel, highly druggable pocket that is the most intracellular allosteric site observed in class A G-protein-coupled receptors so far; this site spatially overlaps the G-protein-binding site in homologous receptors. CCR2-RA-[R] inhibits CCR2 non-competitively by blocking activation-associated conformational changes and formation of the G-protein-binding interface. The conformational signature of the conserved microswitch residues observed in double-antagonist-bound CCR2 resembles the most inactive G-protein-coupled receptor structures solved so far. Like other protein-protein interactions, receptor-chemokine complexes are considered challenging therapeutic targets for small molecules, and the present structure suggests diverse pocket epitopes that can be exploited to overcome obstacles in drug design
Diastereoselective One-Pot Knoevenagel Condensation/Corey–Chaykovsky Cyclopropanation
Efforts to substitute the cyclopropane ring in a series
of aryl
cyclopropylnitriles led to the discovery of an operationally simple
one-pot method for Knoevenagel condensation and subsequent Corey–Chaykovsky
cyclopropanation giving diastereomerically pure products as a racemic
mixture of enantiomers. Method development and results for variably
substituted aryl acetonitriles and aldehydes in the reaction are reported.
A concise synthesis of (±)-bicifadine in two steps is provided
to demonstrate the utility of the method